Thymosin Alpha-1 (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. This 8-week protocol begins at 300 mcg to assess tolerance, then increases to a maintenance dose of 500 mcg daily from Week 2 onward. The 500 mcg daily dose yields ~3.5 mg/week, consistent with clinical dosing ranges. For 10 unit (0.10 mL) or smaller administrations, consider 30- or

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with reconstitution date and refrigerate at 2 to 8 °C, protected from light. At 3.33 mg/mL, 1 unit = 0.01 mL » 33.3 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at 2 to 8 °C for short-term or -20 °C for long-term; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C; use within 7 days when using bacteriostatic water; avoid

freeze-thaw.

• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (Thymosin Alpha-1, 10 mg each):

• 8 weeks: ~3 vials (26.6 mg total).
• 12 weeks: ~5 vials (40.6 mg total).
• 16 weeks: ~6 vials (54.6 mg total).

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (3 vials): 1 bottle. 12 weeks (5 vials): 2 bottles. 16 weeks (6 vials): 2 bottles.

Alcohol Swabs:

• Per week: 14 swabs.
• 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Inspect solution before each use; do not use if cloudy or discolored.

How This Works

Thymosin Alpha-1 is a naturally occurring thymic peptide that modulates immune function through multiple pathways. It enhances the maturation and differentiation of T-cells, augments dendritic cell function, and promotes the production of key cytokines including interferon-a and interleukin-2. Clinical studies have demonstrated Ta1's ability to enhance immune responses in immunocompromised individuals, including those with chronic hepatitis B and C infections. Meta-analyses have also shown benefit in reducing mortality in moderate-to-critical COVID-19 patients.

Benefits & Side Effects

Observations from preclinical and clinical literature.

• Supports enhanced T-cell function and overall immune competence.
• Demonstrates an excellent safety profile; doses up to 1.6 mg twice weekly for 6 to 12 months have been

well-tolerated.

• Even at experimental doses up to 16 mg SC over 12 months, no significant Ta1-specific toxicity has

been observed.

• Most common adverse effect is mild injection-site irritation (redness or discomfort).

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain adequate sleep and stress management to support immune function.
• Consume a nutrient-dense diet rich in vitamins C, D, and zinc.
• Engage in moderate physical activity to complement immune optimization.
• Avoid excessive alcohol and smoking, which impair immune responses.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Dominari et al. Comprehensive review of Thymosin Alpha-1 mechanisms and applications (World Journal of Virology, 2020).
2. Tao et al. Thymosin Alpha-1 in viral diseases (Molecules, MDPI, 2023).
3. Soeroto et al. Meta-analysis of Ta1 in COVID-19 (Inflammopharmacology, 2023).
4. Thymalfasin (Zadaxin) clinical overview: 1.6 mg SC twice weekly for hepatitis B (Expert Opinion on Biological Therapy).